{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-023779","form_type":"8-K","ticker":"IVF","cik":"0001417926","company_name":"INVO Fertility, Inc.","filed_at":"2025-11-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.358242+00:00","generated_at":"2026-05-16T19:10:18.331996+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"INVO Fertility Q3 revenue up 23% to $1.76M; net loss widens to $2.6M","bullets":["Revenue $1,757,094 (+23% YoY); clinic revenue $1,722,223 (+21% YoY).","Net loss $(2.6)M vs $(1.6)M; Adjusted EBITDA $(947,568) vs $(945,949).","INVOcell device revenue grew 130% YoY on training support and pricing.","Company expects to complete at least one acquisition in coming months.","Federal policy change in Oct 2025 allows standalone infertility benefits."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-023779","json":"https://secwatch.observer/filing/0001493152-25-023779.json","markdown":"https://secwatch.observer/filing/0001493152-25-023779.md","text":"https://secwatch.observer/filing/0001493152-25-023779.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1417926/000149315225023779/0001493152-25-023779-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1417926/000149315225023779/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:10:18.331996+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}